Written by: Dr. Wendy Warner, MD, FMCP-M

Symphony Natural Health Science and Medical Team

Reviewed by Dr. Deanna Minich, PhD, MS, CNS, FMCP, FACN

Follicle-stimulating hormone (FSH) is best known as a marker of ovarian decline. However, a growing body of research suggests it may independently influence bone density, fat metabolism, vascular health, and brain aging during the menopausal transition, independent of estradiol.

Historically, the effects of menopause have largely been attributed to estrogen, or estradiol, deficiency. However, a growing body of research suggests that this picture is incomplete. FSH, long relegated to its role in fertility as a marker for ovarian decline, may be more aptly described as a Polyendocrine Synchronization Hormone that reflects the whole-body endocrine state significantly impacting the systemic changes experienced by midlife women.

The Limits of the Estrogen-Only Story in Menopause

Low estradiol levels are a hallmark of menopause. The prevailing narrative suggests that as ovarian estrogen production falls, menopausal symptoms emerge, and the physiological changes associated with menopause begin. Though estrogen undoubtedly plays a central role in endocrine aging, this estrogen-centric model may oversimplify a complex neuroendocrine transition.

FSH levels are shown to rise approximately six years before the final menstrual period, even while estradiol levels are still relatively stable and menstrual cycles are regular [1,2]. In fact, estradiol levels do not steadily decline until late perimenopause, and in some women, estradiol levels increase before the final menstrual period [3,4]. Research suggests that FSH may precede some of the physiological changes associated with menopause, and in certain instances, it may contribute independently of estradiol [3,5].

This has an important clinical implication. If focusing on only estradiol, clinicians may miss early signs of menopause. By the time estradiol reaches menopausal reference ranges, women may already be experiencing systemic changes.

FSH Receptors Show Up in Unexpected Tissues

FSH receptors (FSHR) are expressed on granulosa cells of the ovary and play a critical role in follicle development [6]. However, FSHRs have also been identified in several tissues outside of the ovaries [7].

These include:

• Adipocytes (fat cells) [8]
• Atherosclerotic plaques [9]
• Brain tissue [10]
• Hepatocytes (liver cells) [11]
• Monocytes [12]
• Osteoclasts (bone cells involved in bone resorption) [13]
• Tumor cells [7]

The presence of FSHRs in a variety of cells outside the ovary supports a broader role for FSH as a multi-system endocrine signal.

Four Emerging FSH Targets: Bone, Fat, Vessels, and Brain

Bone

FSHR has a unique presence in bone. Within bone, FSHR expression appears to be concentrated on osteoclasts, which are bone cells responsible for the breakdown or resorption of bone, whereas estradiol influences both osteoblast and osteoclast activity [13]. This suggests that FSH may play a role in tipping the bone remodeling balance toward bone breakdown.

Evidence from the Study of Women's Health Across the Nation (SWAN) suggests that FSH may be a more informative marker of skeletal vulnerability during the menopause transition than estradiol. In this cohort of pre- and perimenopausal women, FSH–but not estradiol–was consistently associated with bone mineral density values in the femoral neck, hip, and lumbar spine [14].

“A biomarker most clinicians already order is quietly outperforming the one they've been trained to watch.”

In the SWAN cohort, FSH, not estradiol, was the hormone consistently linked to bone density at the hip, spine, and femoral neck.

Later research showed that FSH was not only a stronger predictor of bone loss risk, particularly at the lumbar spine, but also that its association with lumbar spine bone mineral density was independent of estradiol [5,15]. This relationship is lost in postmenopause, when FSH levels become stable, suggesting that the rapid rise in FSH during perimenopause may contribute to increased skeletal vulnerability [16,17]. To delve more deeply into this subject, read Dr Doug Lucas' article on Bone and FSH in Menopause.

Fat

FSHR is expressed in fat tissue, where its activation appears to support formation of fat cells, lipid storage, and secretion of adipokines, including leptin and adiponectin, in preclinical research [8]. In some instances, the effect of FSH on fat tissue is independent of estradiol. While estrogen has long been recognized as the primary hormonal regulator of adipose tissue, governing lipid storage, energy expenditure, insulin sensitivity, and the preferential distribution of fat to subcutaneous rather than visceral depots, emerging evidence suggests that FSH may also contribute to adipose tissue biology during the menopausal transition.

Research on the relationship between FSH and adiposity, or body fat accumulation, is nuanced and may be dependent on FSH dynamics. Cross-sectional research suggests an inverse relationship between FSH and adiposity that is independent of estradiol [18]. However, longitudinal research involving postmenopausal women shows that those who experienced the largest increase in FSH also experienced the largest gain in total fat, independent of estradiol [18].

“It's not just how high FSH climbs, it's how fast. Postmenopausal women with the steepest rise in FSH also gained the most total body fat, regardless of what their estradiol was doing.”

FSH has also been associated with reduced lean muscle mass in postmenopausal women, independent of estradiol, suggesting that FSH may influence midlife shifts in body composition [19]. However, it’s likely that FSH interacts with lifestyle, demographic, and metabolic factors, rather than acting as an isolated driver in body composition changes.

Vessels

The relationship between FSH and vascular health looks different depending on the stage of menopause. Although estrogen has traditionally been considered the dominant endocrine regulator of vascular health, preserving endothelial function, arterial elasticity, and vascular homeostasis, accumulating evidence suggests that FSH may also play a stage-dependent role in vascular remodeling during menopause. During the menopause transition, steeper rises in FSH are associated with less favorable vascular profiles, suggesting a role for FSH in early vascular remodeling [20]. This relationship may shift in later postmenopause, where higher FSH levels have been inversely associated with carotid artery wall thickness–a measurement used to assess plaque buildup–independent of estradiol [21].
These findings suggest that the effect of FSH on vascular health may depend on whether levels are actively rising or have plateaued, and on the surrounding metabolic context.

Brain

Although estrogen has traditionally been considered the dominant endocrine regulator of brain health, influencing neuronal metabolism, synaptic function, neuroprotection, and cognitive performance, accumulating evidence suggests that FSH may also play an independent role in neurological aging during the menopausal transition [22,23]. Emerging research suggests that FSH may independently influence neurological aging and cognitive changes [24,25]. In midlife women, higher FSH levels were associated with reduced gray matter volume in frontal brain regions and increased β-amyloid deposition, even after adjusting for estradiol and hormone therapy use[26]. Whereas gray matter is essential for normal cognitive functioning, β-amyloid appears to be involved in neurodegenerative processes [27,28]. The effects were detectable in both peri- and postmenopause, though they were most pronounced in postmenopausal women.

Further, FSH may indirectly contribute to neurological aging through systemic metabolic effects, including changes in lipid metabolism and inflammatory balance. Though this remains an active area of research, it suggests that FSH may provide insight into cognitive changes before they become apparent.

Reframing Menopause as Endocrine Aging

Taken together, these findings invite a shift in framing: rather than viewing menopause purely as estrogen deficiency, it may be more accurate to think of it as a more expansive process of endocrine aging, in which a rising, increasingly independent FSH signal coincides with and possibly contributes to changes across the skeleton, fat tissue, vasculature, and brain.
This is clinically relevant because FSH already sits in most clinicians' toolkits. Reframing it from a static menopause cutoff to a dynamic, stage-dependent biomarker could prove useful in risk assessment, particularly for early bone loss, where a single FSH threshold may not work as well as tracking trends over time alongside other risk factors.
Not to mention progesterone, testosterone, LH, cortisol, glucagon, melatonin and so much more. For the latest from our medical team on supporting the entire endocrine system and hormones through menopause, there is our 20-module course here.

What's Next for FSH?

Menopause is an evolving area of research and clinical practice.

Future research involving FSH levels in peri- and postmenopausal women may:

• Utilize interventional studies that use FSH as an outcome measurement
• Clarify causality vs. association, especially in metabolism and vascular health
• Provide stage-specific reference ranges, particularly for bone health screening
• Elucidate the effects of FSHR genetic polymorphisms that may explain why some individuals may be more sensitive to FSH fluctuations than others

For clinicians, FSH screening can serve as a valuable biomarker reflecting broader HPO activity and systemic aging during the menopausal transition, especially when assessed prior to estradiol decline.

Tracking FSH trends across perimenopause, rather than waiting for estradiol to confirm what's already underway, may provide practitioners with earlier insight into physiological changes affecting skeletal, metabolic, vascular, and cognitive health.

Dr. Wendy Warner

MD, FMCP-M · Symphony Medical Team · Southeastern PA, telemedicine practice · 36 years in practice

Board-certified OB/GYN and functional medicine gynecologist. MD, University of Tennessee Health Science Center; OB/GYN residency, Temple University Hospital. Founded Medicine in Balance after 14 years in conventional practice; moved fully to telemedicine in 2022. Board certified in both gynecology and integrative holistic medicine, past president of the American Board of Integrative Holistic Medicine, authored the menopause chapter in Rakel's Integrative Medicine (5th ed.), co-author of Boosting Your Immunity for Dummies. Trained herbalist; faculty for David Winston's Center for Herbal Studies and educator for the Institute for Functional Medicine’s Hormone Advanced Practice Module. Nationally recognized speaker and educator.

References

1. Randolph JF Jr, Zheng H, Sowers MR, et al. J Clin Endocrinol Metab. 2011;96(3):746-754. doi:10.1210/jc.2010-1746
2. Delamater L, Santoro N. Clin Obstet Gynecol. 2018;61(3):419-432. doi:10.1097/GRF.0000000000000389
3. Harlow SD, Gass M, Hall JE, et al. J Clin Endocrinol Metab. 2012;97(4):1159-1168. doi:10.1210/jc.2011-3362
4. Tepper PG, Randolph JF Jr, McConnell DS, et al. J Clin Endocrinol Metab. 2012;97(8):2872-2880. doi:10.1210/jc.2012-1422
5. Ramírez Stieben LA, Brun LR, Pustilnik E, et al. Calcif Tissue Int. 2025;116(1):137. Published 2025 Dec 1. doi:10.1007/s00223-025-01450-1
6. Holesh JE, Bass AN, Lord M. Treasure Island (FL): StatPearls Publishing; May 1, 2023.
7. Chrusciel M, Ponikwicka-Tyszko D, Wolczynski S, Huhtaniemi I, Rahman NA. Front Endocrinol (Lausanne). 2019;10:32. Published 2019 Feb 4. doi:10.3389/fendo.2019.00032
8. Liu XM, Chan HC, Ding GL, et al. Aging Cell. 2015;14(3):409-420. doi:10.1111/acel.12331
9. Ghinea N, Liehn EA, Grommes J, Delattre DD, Olesen TK. Sci Rep. 2024;14(1):10176. Published 2024 May 3. doi:10.1038/s41598-024-60962-2
10. Ryu V, Gumerova A, Korkmaz F, et al. Elife. 2022;11:e79612. Published 2022 Sep 2. doi:10.7554/eLife.79612
11. Song Y, Wang ES, Xing LL, et al. J Clin Endocrinol Metab. 2016;101(1):254-263. doi:10.1210/jc.2015-2724
12. Robinson LJ, Tourkova I, Wang Y, et al. Biochem Biophys Res Commun. 2010;394(1):12-17. doi:10.1016/j.bbrc.2010.02.112
13. Chin KY. Int J Med Sci. 2018;15(12):1373-1383. Published 2018 Sep 7. doi:10.7150/ijms.26571
14. Sowers MR, Finkelstein JS, Ettinger B, et al. Osteoporos Int. 2003;14(1):44-52. doi:10.1007/s00198-002-1307-x
15. Shieh A, Greendale GA, Cauley JA, Karvonen-Gutierrez C, Crandall CJ, Karlamangla AS. J Bone Miner Res. 2019;34(12):2246-2253. doi:10.1002/jbmr.3856
16. Crandall CJ, Tseng CH, Karlamangla AS, et al. J Clin Endocrinol Metab. 2013;98(4):E654-E663. doi:10.1210/jc.2012-3651
17. Wu KC, Ewing SK, Li X, et al. J Clin Endocrinol Metab. 2021;106(10):2876-2889. doi:10.1210/clinem/dgab481
18. Mattick LJ, Bea JW, Singh L, et al. J Clin Endocrinol Metab. 2022;107(8):e3455-e3462. doi:10.1210/clinem/dgac238
19. Park YM, Jankowski CM, Ozemek C, Hildreth KL, Kohrt WM, Moreau KL. J Appl Physiol (1985). 2020;128(5):1373-1380. doi:10.1152/japplphysiol.00315.2019
20. El Khoudary SR, Santoro N, Chen HY, et al. Eur J Prev Cardiol. 2016;23(7):694-703. doi:10.1177/2047487315607044
21. Bertone-Johnson ER, Virtanen JK, Nurmi T, et al. Am J Epidemiol. 2018;187(1):16-26. doi:10.1093/aje/kwx174
22. Webber KM, Casadesus G, Marlatt MW, et al. Ann N Y Acad Sci. 2005;1052:201-209. doi:10.1196/annals.1347.020
23. Casadesus G, Garrett MR, Webber KM, et al. Drugs R D. 2006;7(3):187-193. doi:10.2165/00126839-200607030-00004
24. Wang SM, Jeong C, Um YH, et al. Front Aging Neurosci. 2026;17:1697255. Published 2026 Jan 6. doi:10.3389/fnagi.2025.1697255
25. Ding C, Xu X, Xu B, Wu J. Ann Hum Genet. 2026;90(1):25-40. doi:10.1111/ahg.70004
26. Nerattini M, Rubino F, Jett S, et al. Front Dement. 2023;2:1303256. doi:10.3389/frdem.2023.1303256
27. Mercadante AA, Tadi P. Treasure Island (FL): StatPearls Publishing; July 24, 2023.
28. Rukmangadachar LA, Bollu PC. Treasure Island (FL): StatPearls Publishing; April 27, 2025.